Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.27
-0.11 (-0.42%)
At close: Sep 24, 2026, 4:00 PM EDT
26.25
-0.02 (-0.08%)
After-hours: Sep 24, 2026, 7:30 PM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 354 employees as of December 31, 2025. The number of employees increased by 12 or 3.51% compared to the previous year.
Employees
354
Change (1Y)
12
Growth (1Y)
3.51%
Revenue / Employee
$1,310,681
Profits / Employee
$80,562
Market Cap
3.30B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 354 | 12 | 3.51% |
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Sep 30, 2021 | 143 | 90 | 169.81% |
| Jun 30, 2021 | 108 | 59 | 120.41% |
| Mar 31, 2021 | 75 | 32 | 74.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| Denali Therapeutics | 507 |
| Tarsus Pharmaceuticals | 370 |
| Xenon Pharmaceuticals | 370 |
| Dyne Therapeutics | 289 |
| uniQure | 221 |
ARQT News
- 7 days ago - Arcutis Biotherapeutics falls -5.1% - TheFly
- 8 days ago - Arcutis Biotherapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 8 days ago - Arcutis Biotherapeutics rises 7.7% - TheFly
- 20 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 23 days ago - Arcutis Biotherapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Oruka Therapeutics appoints Todd Edwards as chief commercial officer - TheFly
- 7 weeks ago - Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley - TheFly